logo
  

IDEXX Laboratories Slashes FY22 Outlook - Update

While reporting financial results for the second quarter on Tuesday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) slashed its earnings and revenue growth guidance for the full-year 2022.

For fiscal 2022, the company now projects earnings in a range of $7.77 to $8.05 per share on revenues between $3.305 billion and $3.385 billion, with revenue growth of 3 to 5.5 percent and organic revenue growth of 5.5 to 8 percent.

Previously, the company expected earnings in a range of $8.11 to $8.35 per share on revenue growth of 5.5 to 8 percent and organic revenue growth of 7.5 to 10 percent.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $8.27 per share on revenues of $3.42 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Unemployment data from Spain and producer prices from the euro area are due on Tuesday, headlining a light day for the European economic news. At 2.00 am ET, the National Institute of Statistics is scheduled to issue Romania's producer prices for August. Australia's central bank raised its benchmark rate by a quarter-point to bring inflation back to the target range. The policy board of the RBA, headed by Governor Philip Lowe, decided to lift the cash rate target by 25 basis points to 2.60 percent from 2.35 percent. This was the highest rate since... Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday.
RELATED NEWS
Follow RTT